Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) after 36 ...

Efruxifermin also appeared to be associated with improvements in MASH-related histologic findings, noninvasive markers of liver injury and fibrosis, and markers of glucose and lipid metabolism.

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why AKRO stock is a Strong Buy.

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1241 in Combination with Efruxifermin Shows Enhanced ...

Treatment with efruxifermin resulted in significant improvement in fibrosis at week 24 in patients with metabolic dysfunction-associated steatohepatitis, which was “sustained and expanded ...

Efruxifermin is a fusion protein that serves as an analog of fibroblast growth factor 21, or FGF21. This hormone found in the body protects against cellular stress and also regulates metabolism.

Key Takeaways. Efruxifermin (EFX) with GLP-1RA significantly reduces hepatic fat fraction and improves fibrosis in MASH and T2D patients. The study involved 31 patients over 12 weeks, showing EFX ...

More efruxifermin patients also achieved improvements in liver fat content, with a mean relative percent change from baseline of -64% with the 50-mg dose and -52% with the 28-mg dose compared with ...

Efruxifermin with a glucagon-like peptide-1 receptor agonist was well-tolerated and reduced hepatic fat fraction and noninvasive markers of fibrosis among patients with metabolic dysfunction ...

Because efruxifermin is not a native polypeptide, one concern is its immunogenicity. In one study , 41 of 57 subjects developed antibodies to the drug, albeit at low titers, but both fibrosis and ...